[ad_1] (Reuters) – Vir Biotechnology Inc and Alnylam Pharmaceuticals Inc have identified a drug candidate for treating COVID-19 and plan to begin human testing by the end of the year, the companies said on Monday.
Vir, Alnylam identify COVID-19 therapy candidate, plan human trials by year end
